Cardiovascular risk factors in non-insulin-dependent diabetics compared to non-diabetic controls: A population-based survey among Asians in Singapore

Atherosclerosis

Volumn 136, Issue 1, 1998, Pages 25-31

  Hughes, Kenneth ^a   Choo, Maurice ^b   Kuperan, Ponnudurai ^b   Ong, Choon Nam ^a   Aw, Tar Choon ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Anti oxidants; Atherosclerosis; Haemostasis; Lipids; Lipoproteins; Obesity; Pro oxidants

Indexed keywords

FERRITIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ASIAN; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEMOSTASIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION RISK; PRIORITY JOURNAL; RISK FACTOR; SINGAPORE; SYNDROME X;

ARTERIOSCLEROSIS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHINA; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; INDIA; MALAYSIA; MALE; POPULATION SURVEILLANCE; PREVALENCE; PROGNOSIS; RISK FACTORS; SINGAPORE; THROMBOSIS;

EID: 0031852592     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00180-9     Document Type: Article

References (36)

1. Pyorala K., Iaakso M., Uusitupa M. Diabetes and atherosclerosis an epidemiologic view. Diabetes Metab Rev. 3:1987;463-524.
2. Stern M.P., Haffner S.M. Body fat distribution and hyperinsulinaemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis. 6:1986;123-130.
3. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
4. Nordoy A. Haemostatic factors in coronary heart disease. J Intern Med. 233:1993;377-383.
5. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev. 75:1995;473-486.
6. Scanu A.M., Lawn R.M., Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med. 115:1991;209-218.
7. Hajjar K.A., Gavish D., Breslow J.L., Hachman R.L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:1989;303-305.
8. Lip G.Y., Jones A.F. Lipoprotein(a) and vascular disease: thrombosis and atherogenesis. Q J Med. 88:1995;529-539.
9. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA. 90:1993;7915-7922.
10. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis. 98:1993;1-9.
11. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet. 344:1994;721-724.
12. van Poppel G., Kardinaal A., Princen H., Kok F.J. Antioxidants and coronary heart disease. Ann Med. 26:1994;429-434.
13. Ascherio A., Willett W.C. New directions in dietary studies of coronary heart disease. J Nutr. 125(Suppl 3):1995;S647-655.
14. Burt M., Halliday J.W., Powell L.W. Iron and coronary heart disease. Br Med J. 307:1993;575-576.
15. Hughes K., Lun K.C., Yeo PPB Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. I Differences in mortality. J Epidemiol Community Health. 44:1990;24-28.
16. Hughes K., Yeo PPB, Lun K.C., Thai A.C., Sothy S.P., Wang K.W., Cheah J.S., Phoon W.O., Lim P. Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. II. Differences in risk factor levels. J Epidemiol Community Health. 44:1990;29-35.
17. Hughes K, Aw TC, Kuperan P, Choo M, Central obesity, insulin resistance, syndrome X, lipoprotein(a) and cardiovascular risk in Indians, Malays and Chinese in Singapore. J Epidemiol Community Health 1997;51:394-9.
18. World Health Organization. Multinational monitoring of trends and determinants in cardiovascular diseases, 'Monica Project': Manual of Operations. Geneva: World Health Organization, 1982.
19. Liau L.S., Lee B.L., New A.L., Ong C.N. Determination of plasma ascorbic acid by high-performance liquid chromatography with ultraviolet and electrochemical detection. J Chromatogr. 612:1993;63-70.
20. Lee B.L., Chua S.C., Ong H.Y., Ong C.N. High-performance liquid chromatographic method for routine determination of vitamins A and E and beta-carotene in plasma. J Chromatogr. 581:1992;41-47.
21. WHO Study Group. Prevention of diabetes mellitus. WHO Tech Rep Ser 1994;844:1-100 (p. 18).
22. WHO Study Group on Diabetes Mellitus. Diabetes Mellitus. WHO Tech Rep Ser 1985;727:1-113.
23. Hughes K., Yeo PPB, Lun K.C., Sothy S.P., Thai A.C., Wang K.W., Chea J.S. Ischaemic heart disease and its risk factors in Singapore in comparison with other countries. Ann Acad Med Singapore. 18:1989;245-249.
24. Kannel W.B., D'Agostino R.B., Wilson P.W., Belanger A.J., Gagnon D.R. Diabetes, fibrinogen, and risk of cardiovascular disease: The Framingham experience. Am Heart J. 120:1990;672-676.
25. Steiner G. From an excess of fat, diabetics die. J Am Med Assoc. 262:1989;398-399.
26. Morishita E., Asakura H., Jokaji H., Saito M., Uotani C., Kumabashiri I., Yamazaki M., Aoshima K., Hashimoto T., Matsuda T. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis. 120:1996;7-14.
27. Chang C.J., Kao J.T., Wu T.J., Lu F.H., Tai T.Y. Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients. Relation to metabolic control. Diabetes Care. 18:1995;1191-1194.
28. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease. Thromb Haemost. 74:1995;71-76.
29. Auwerx J., Bouillon R., Collen D., Geboers J. Tissue-type plasminogen activator and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 8:1988;68-73.
30. ECAT angina pectoris study. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993;14:8-17.
31. Rydzewski A., Kawamura H., Watanabe I., Takada T., Takada A. Plasminogen activators and plasminogen activator inhibitor (PAI-1) in type II diabetes mellitus. Fibrinolysis. 4:1990;183-188.
32. Chan P., Pan W.H. Coagulation activation in type 2 diabetes mellitus: the higher coronary risk of female diabetic patients. Diabetic Med. 12:1995;504-507.
33. Heller F.R., Galanti L., Jamart J., Parfonry A., Honore P., Hondekijin J.-C., Derue G., Buysschaert M., Novik V. Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care. 16:1993;819-823.
34. Rainwater D.L., MacCluer J.W., Stern M.P., Vandeberg J.L., Haffner S.M. Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes. 43:1994;942-946.
35. Editorial. Lipoprotein(a). Lancet 1991;337:397-398.
36. Fairbanks VF. Iron in medicine and nutrition. In: Shils ME, lson JA, Shike M, editors. Modern Nutrition in Health and Disease. Philadelphia: Lea and Febiger, 1994:185-213.